160 related articles for article (PubMed ID: 12599085)
1. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
2. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
3. Generation of a parvovirus B19 vaccine candidate.
Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
5. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
[TBL] [Abstract][Full Text] [Related]
7. Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus.
Molina A; Veramendi J; Hervás-Stubbs S
Virology; 2005 Nov; 342(2):266-75. PubMed ID: 16140352
[TBL] [Abstract][Full Text] [Related]
8. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo cytokine responses against parvovirus B19 antigens in previously infected pregnant women.
Corcoran A; Mahon BP; McParland P; Davoren A; Doyle S
J Med Virol; 2003 Jul; 70(3):475-80. PubMed ID: 12767014
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
11. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19.
Franssila R; Hokynar K; Hedman K
J Infect Dis; 2001 Mar; 183(5):805-9. PubMed ID: 11181158
[TBL] [Abstract][Full Text] [Related]
12. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
[TBL] [Abstract][Full Text] [Related]
13. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by a goose parvovirus vaccine in ducks.
Lee JW; Lin YM; Yen TY; Yang WJ; Chu CY
Vaccine; 2010 Nov; 28(50):7956-62. PubMed ID: 20933041
[TBL] [Abstract][Full Text] [Related]
15. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
16. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
17. Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen.
Ogasawara Y; Amexis G; Yamaguchi H; Kajigaya S; Leppla SH; Young NS
In Vivo; 2006; 20(3):319-24. PubMed ID: 16724664
[TBL] [Abstract][Full Text] [Related]
18. Candidate recombinant vaccine for human B19 parvovirus.
Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
Coyne MJ
Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
[TBL] [Abstract][Full Text] [Related]
20. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
